Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
Petersohn S, McGregor B, Klijn SL, May JR, Ejzykowicz F, Kurt M, Dyer M, Malcolm B, Branchoux S, Nickel K, George S, Kroep S. Petersohn S, et al. Among authors: may jr. J Comp Eff Res. 2023 Aug;12(8):e230004. doi: 10.57264/cer-2023-0004. Epub 2023 Jul 11. J Comp Eff Res. 2023. PMID: 37431849 Free PMC article. Review.
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N, Decimoni TC, Dyer MTD, May JR, van de Wetering G, Petersohn S, Nickel K, Silva A, Muniz DQB, Casagrande D Oliveira AP. Dhanji N, et al. Among authors: may jr. J Med Econ. 2023 Jan-Dec;26(1):1108-1121. doi: 10.1080/13696998.2023.2252716. J Med Econ. 2023. PMID: 37632452 Free article.
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C. McGregor B, et al. Among authors: may jr. Eur Urol Oncol. 2023 Jun;6(3):339-348. doi: 10.1016/j.euo.2023.01.012. Epub 2023 Feb 25. Eur Urol Oncol. 2023. PMID: 36842942 Free article.
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya S, Mishra D, Bhattacharyya D, Dalal AA. Mistry R, et al. Among authors: may jr. J Manag Care Spec Pharm. 2018 Jun;24(6):514-523. doi: 10.18553/jmcp.2018.24.6.514. J Manag Care Spec Pharm. 2018. PMID: 29799329 Free PMC article.
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Mistry R, Suri G, Young K, Hettle R, May JR, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal AA. Mistry R, et al. Among authors: may jr. Curr Med Res Opin. 2018 Dec;34(12):2143-2150. doi: 10.1080/03007995.2018.1503484. Epub 2018 Aug 17. Curr Med Res Opin. 2018. PMID: 30032697
431 results